Latest report
H1 2026
Organic recovery, but earnings and deal risk remain
Read latest report
Amplifon Investor Reports
Global hearing-care retailer with coverage from 2024 onward.
Latest analysis
Report archive
| Period | Status | Brief | Action |
|---|---|---|---|
| H1 2026 | Analyzed | Organic recovery, but earnings and deal risk remain | View report |
| Q1 2026 | Analyzed | Recovery signs, major deal risk | View report |
| FY 2025 | Analyzed | Stalled growth, recovery plan unproven | View report |
| 9M 2025 | Analyzed | Flat revenue, falling profit, rising debt | View report |
| H1 2025 | Analyzed | Guidance cut confirms broad deterioration | View report |
| Q1 2025 | Analyzed | Record EBITDA margin, weaker earnings quality | View report |
| FY 2024 | Analyzed | Growth at a cost: Debt up, Margins down | View report |
| 9M 2024 | Analyzed | Revenue growth masks margin deterioration | View report |
| H1 2024 | Analyzed | Growth continues, cash conversion weakens | View report |
| Q1 2024 | Analyzed | Strong start, acquisition-heavy cash use | View report |
H1 2026Analyzed
Organic recovery, but earnings and deal risk remain
View report →
Q1 2026Analyzed
Recovery signs, major deal risk
View report →
FY 2025Analyzed
Stalled growth, recovery plan unproven
View report →
9M 2025Analyzed
Flat revenue, falling profit, rising debt
View report →
H1 2025Analyzed
Guidance cut confirms broad deterioration
View report →
Q1 2025Analyzed
Record EBITDA margin, weaker earnings quality
View report →
FY 2024Analyzed
Growth at a cost: Debt up, Margins down
View report →
9M 2024Analyzed
Revenue growth masks margin deterioration
View report →
H1 2024Analyzed
Growth continues, cash conversion weakens
View report →
Q1 2024Analyzed
Strong start, acquisition-heavy cash use
View report →